CoronaryAtlas logo
CoronaryAtlas
Apolipoprotein B
Pathway / Lipid retention & oxidation

Apolipoprotein B

APOBprotein

ApoB-containing lipoproteins are retained in the subendothelium and oxidatively modified, initiating atherogenesis.

Pathway placement
Cascade stepLipid retention & oxidation
Confidencehigh
RationaleApoB is the structural protein of atherogenic lipoproteins; substrate for LDL oxidation.
Druggability
DruggableYes
Known drugs / candidates2
Small-molecule tractableYes
Antibody tractableYes
EnsemblENSG00000084674

Type I vs non-Type I discrimination

ScoresShared / rises in both
R — rupture / Type-I
67
C — non-Type-I
67
A — assay feasibility
84
E — evidence strength
60
T1DI (composite)
25
Specificity differential (R−C)0
Non-Type-I axis panel
Does this marker also move in each non-Type-I setting? mag 0–3; higher means less Type-I-specific. n/a = no evidence retrieved, which is not the same as no change.
2sepsis / systemic inflammationmag 2
2anemia / acute blood lossn/a
2hypovolemia / dehydrationmag 2
2tachyarrhythmian/a
2hypoxemia / respiratory failuren/a
2hypertensive emergencyn/a
2high-demand / peri-operative stressmag 2
3sudden cardiac deathmag 2
4aPCI-related periproceduraln/a
4bstent thrombosisn/a
4cin-stent restenosismag 2
5CABG-relatedmag 2
Coverage: 6/12 axes with evidence
Tier: deep-scored (abstract-extracted) · 17 supporting references. See the discrimination table for all markers.

Assay & specimen

Validated clinical assay
Specimen
Serum or plasma
Collection tube
Serum separator (gold/red-top, SST)
Method / principle
Immunoturbidimetric/nephelometric
Reagent / substrate
Anti-apoB antibody-latex
Platform
Automated analyzer
Turnaround · availability
Routine · Universal

Human genetic evidence

0.534
Open Targets association (myocardial_infarction)
2
GWAS associations
Traits: myocardial infarction

Literature evidence(49)

Showing 40 of 49 linked references.

Clinical trials(3)